d- Opioid receptor agonists inhibit migraine- related hyperalgesia, aversive state and cortical spreading depression in mice

Background and PurposeMigraine is an extraordinarily common brain disorder for which treatment options continue to be limited. Agonists that activate the -opioid receptor may be promising for the treatment of migraine as they are highly effective for the treatment of chronic rather than acute pain, do not induce hyperalgesia, have low abuse potential and have anxiolytic and antidepressant properties. The aim of this study was to investigate the therapeutic potential of -opioid receptor agonists for migraine by characterizing their effects in mouse migraine models. Experimental ApproachMechanical hypersensitivity was assessed in mice treated with acute and chronic doses of nitroglycerin (NTG), a known human migraine trigger. Conditioned place aversion to NTG was also measured as a model of migraine-associated negative affect. In addition, we assessed evoked cortical spreading depression (CSD), an established model of migraine aura, in a thinned skull preparation. Key ResultsNTG evoked acute and chronic mechanical and thermal hyperalgesia in mice, as well as conditioned place aversion. Three different -opioid receptor agonists, SNC80, ARM390 and JNJ20788560, significantly reduced NTG-evoked hyperalgesia. SNC80 also abolished NTG-induced conditioned place aversion, suggesting that -opioid receptor activation may also alleviate the negative emotional state associated with migraine. We also found that SNC80 significantly attenuated CSD, a model that is considered predictive of migraine preventive therapies. Conclusions and ImplicationsThese data show that -opioid receptor agonists modulate multiple basic mechanisms associated with migraine, indicating that -opioid receptors are a promising therapeutic target for this disorder.